Table 2 Characteristics of eligible studies

Weizman et al. 2021

Israel

Individuals With Schizophrenia

35.2

41.6

12

10

8

Bupropion SR (150–300 mg/d)

35

Weight, BMI

McIntyre et al. 2021

Canada

Patients with Obesity or Overweight

61.6

53

890

585

104

Naltrexone SR( 32 mg/day) with bupropion SR (360 mg/day)

36.9

Weight

Wadden et al. 2011

USA

Patients with Obesity or Overweight

45.9

10.7

591

202

56

Naltrexone SR ( 32 mg/day) with bupropion SR (360 mg/day)

36.3

Weight, WC

Jain et al. 2002

USA

Obese Patients with Depressive Symptoms

46

11

213

209

26

Bupropion SR (300 mg/day)

36

Weight

Hong et al. 2016

USA

Patients with Obesity or Overweight

44.8

17.1

1489

1176

56

Naltrexone SR (32 mg/day) with bupropion SR (360 mg/day)

36.2

Weight

Cho et al. 2020

Republic of Korea

Obese Breast Cancer Survivors

56

0

14

20

8

Naltrexone (8 mg/day) with bupropion (90 mg/day)

27.6

Weight, BMI

Hollander et al. 2013

USA

Overweight/obese individuals with type 2 diabetes

54

46

265

159

56

Naltrexone SR ( 32 mg/day) with bupropion SR (360 mg/day)

37

Weight, WC

Halseth et al. 2016

USA

Obesity

46.1

18.3

71

82

26

Naltrexone SR (32 mg/day) with bupropion SR (360 mg/day)

36.33

Weight, WC

Lyu et al. 2018

USA

Obese male schizophrenia patients

54.3

100

11

10

24

Naltrexone SR ( 24 mg/day) with bupropion SR (300 mg/day)

26.1

Weight, BMI

Bajaj et al. 2020

Canada

Adults with overweight or obesity

NR

21

1310

763

56

Naltrexone SR ( 32 mg/day) with bupropion SR (360 mg/day)

36.2

Weight

Greenway et al. 2009

USA

Obesity

42.6

13.3

36,32, 38, 18

84

24

Bupropion SR (400 mg/d), naltrexone SR (16, 32, or 48 mg/day) with bupropion SR (400 mg/day)

35.1

Weight, WC

Greenway et al. 2010

USA

Overweight and obese adults

44.4

11.5

471, 471

511

56

Naltrexone SR (16 mg/day) wit bupropion SR (360 mg/day)

36.1

Weight, WC

Apovian et al. 2013

USA

Overweight and obese participants

44.3

15

434

267

56

Naltrexone SR (32 mg/day) with bupropion SR (360 mg/day)

36.2

Weight, WC

Nissen et al. 2016

USA

Overweight and Obese Patients With Cardiovascular Risk Factors

61

15

4455

4450

104

Naltrexone SR (32 mg/day) with bupropion SR (360 mg/day)

36.6

Weight, WC

Gadde et al. 2001

USA

Patients with Obesity or Overweight women

40.4

15.4

25

25

8

Naltrexone SR (32 mg/day) with bupropion SR (360 mg/day)

36.9

Weight

Smith et al. 2013

USA

Obese subjects

46

45.5

8, 41

19

24

Bupropion SR (400 mg/d)/ Naltrexone SR (48 mg/day) with bupropion SR (400 mg/day)

358

Weight, WC

Croft et al. 2002

USA

Patients with Major Depression

39.4

NR

210

213

52

Bupropion SR (300 mg/d)

28.74

Weight

Grilo et al. 2022

USA

Binge-Eating Disorder

46.5

18.4

32

34

16

Naltrexone SR (32 mg/day) with bupropion SR (360 mg/day)

37.1

Weight

Anderson et al. 2002

USA

Obese adults

43.9

16.3

110, 105

112

48

Bupropion SR (300 or 400 mg/d)

36.5

Weight, WC

Wharton et al. 2021

Canada

Subjects with type 2 diabetes

60.7

44.9

165

96

52

Naltrexone SR (32 mg/day) with bupropion SR (360 mg/day)

37.5

Weight

Settle et al. 1999

USA

Depressed outpatients.

38.9

35

113, 111

347

8

Bupropion SR (200 or 400 mg/d)

NR

Weight

Weihs et al. 2002

USA

Patients with recurrent major depression

39.4

34

210

213

8

Bupropion SR (300 mg/d)

NR

Weight

Grilo et al. 2020

USA

Binge-eating Disorder with Obesity

50.4

13.6

9

7

12

Naltrexone SR (50 mg/day) with bupropion SR (300 mg/day)

27.6

BMI

White et al. 2013

USA

Overweight and obese women

44.15

0

31

30

8

Bupropion SR (300 mg/d)

35.8

BMI

Billes et al. 2011

USA

Obese subjects

NR

NR

273

277

56

Naltrexone SR (16 or 32 mg/day) wit bupropion SR (360 mg/day)

NR

WC